Bromocriptine reduces endometrial cell growth in women with adenomyosis by targeting glucose metabolism

The primary aim of this study is to study the molecular changes in the endometrium of women with diffuse adenomyosis at baseline and after treatment with six months of vaginal bromocriptine, as a secondary outcome of a clinical trial.  Pictorial Blood Loss Assessment Chart (PBLAC) was used to assess the amount of menstrual bleeding. The results suggest an anti-proliferative effect of bromocriptine in the endometrium in women with adenomyosis achieved by regulating genes associated with glucose metabolism. We speculate that the above mechanism could explain the reduced bleeding and pain observed in women with adenomyosis after bromocriptine treatment. The current study is a single arm, pre-post intervention study in a University-hospital initiated clinical trial. Twelve women diagnosed with diffuse adenomyosis were administered for six months with a daily dose of 5mg vaginal bromocriptine. Endometrial biopsies were collected at baseline and at the end of treatment.